Latest news with #HME
Yahoo
24-07-2025
- Business
- Yahoo
Here's What to Expect From ResMed's Next Earnings Report
ResMed Inc. (RMD), headquartered in San Diego, California, manufactures, distributes, and markets medical devices and cloud-based software applications. Valued at $39.2 billion by market cap, the company offers a range of products for respiratory disorders, including diagnostic tools like ApneaLink Air and NightOwl, cloud-based platforms like AirView and myAir for patient monitoring, and U-Sleep for HME providers, connectivity solutions, as well as out-of-hospital software solutions. The sleep tech giant is expected to announce its fiscal fourth-quarter earnings for 2025 after the market closes on Thursday, Jul. 31. Ahead of the event, analysts expect RMD to report a profit of $2.47 per share on a diluted basis, up 18.8% from $2.08 per share in the year-ago quarter. The company has consistently surpassed Wall Street's EPS estimates in its last four quarterly reports. More News from Barchart NVDA Broken Wing Butterfly Trade Targets A Profit Zone Between 150 and 160 Is Opendoor Stock a Buy at New 52-Week Highs? Billionaire Peter Thiel is Betting Big on Stablecoins. Should You Buy the "MicroStrategy of Ethereum," Too? Get exclusive insights with the FREE Barchart Brief newsletter. Subscribe now for quick, incisive midday market analysis you won't find anywhere else. For the full year, analysts expect RMD to report EPS of $9.50, up 23.1% from $7.72 in fiscal 2024. Its EPS is expected to rise 10.2% year over year to $10.47 in fiscal 2026. RMD stock has outperformed the S&P 500 Index's ($SPX) 14.5% gains over the past 52 weeks, with shares up 30.5% during this period. Similarly, it outperformed the Health Care Select Sector SPDR Fund's (XLV) 8.3% dip over the same time frame. RMD's recent success is driven by the introduction of a range of masks in its AirFit and AirTouch series, as well as advancements in its therapy-based software solutions, such as AirView, which have performed well in the U.S. market. RMD is also investing in artificial intelligence capabilities to improve patient adherence and outcomes. Cost reduction strategies, improved production processes, and new product launches have contributed to the company's positive performance. The company is focused on global brand unification and expanding manufacturing capacity to support market growth. Furthermore, the U.S. tariff exemptions for its medical devices provide further stability. On Apr. 23, RMD reported its Q3 results, and its shares closed up more than 10% in the following trading session. Its adjusted EPS of $2.37 exceeded Wall Street expectations of $2.36. The company's revenue was $1.29 billion, beating Wall Street forecasts of $1.28 billion. Analysts' consensus opinion on RMD stock is reasonably bullish, with an overall 'Moderate Buy' rating. Out of 17 analysts covering the stock, nine advise a 'Strong Buy' rating, two suggest a 'Moderate Buy,' five give a 'Hold,' and one recommends a 'Strong Sell.' While RMD currently trades above its mean price target of $266.25, the Street-high price target of $294 suggests an upside potential of 7.5%. On the date of publication, Neha Panjwani did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
27-06-2025
- Health
- Yahoo
Trella Health Launches Its Latest Medicare Advantage (MA) Data to Help Post-Acute Providers Thrive in the Expanding MA Market
Now available in Marketscape Insights, this upgraded dataset delivers greater visibility into Medicare Advantage referral patterns, payer trends, patient flows, and additional strategic insights. ATLANTA, June 27, 2025 /PRNewswire/ -- Trella Health, the leading source for actionable post-acute analytics and insights, today announced the release of its Latest Medicare Advantage (MA) Data — a comprehensive new dataset designed to empower home health and skilled nursing organizations to thrive in the rapidly expanding MA market. With Medicare Advantage enrollment surpassing traditional Medicare — now accounting for 55.4% of all Medicare beneficiaries — the demand for timely, targeted, and granular MA insights is reshaping provider growth strategies in an MA-first landscape. This release delivers payer-level referral intelligence — offering unprecedented visibility into where MA patients come from, where they're referred, and where strategic referral relationships are taking shape across hospitals, physicians, and post-acute providers. "As Medicare Advantage continues to grow, providers need deeper visibility into referral behavior, patient flow, and payer dynamics," said Kathy Ford, Chief Product Officer at Trella Health. "This new dataset unlocks critical insights that help our users align their network strategies with high-value MA opportunities." The Latest MA Data Upgrade is available as an add-on to Trella's Marketscape Insights platform for both home health and skilled nursing users, with data refreshed quarterly in alignment with Trella's fee-for-service update schedule. This enhanced MA dataset enables users to: Identify High-Value MA Referral Sources: discover hospitals and physicians referring MA patients to Skilled Nursing Facilities (SNFs) and Home Health Agencies (HHAs) using metrics such as payer name, annual patient counts, and affiliation percentages. Evaluate MA Payer Trends and Strategic Alignment: assess trends in MA volumes using annual patient counts and payer-specific referral data to identify providers treating target populations. Monitor Referral Leakage and Strengthen Relationships: track MA patient movement using referral destination data, affiliation percentages, and facility-level patient counts to uncover referral shifts over time. Trella Health's latest Medicare Advantage data release reflects the company's continued investment in data innovation — expanding access to timely, targeted insights that support smarter growth, value-based care strategies, and improved patient outcomes. For more information or to request a demo, visit About Trella HealthTrella Health's unmatched market intelligence and purpose-built CRM allow post-acute providers, HME, and Infusion organizations to drive more effective performance and growth. Trella's solutions allow post-acute, HME, and Infusion organizations to identify the highest-potential referral targets, evaluate new market opportunities, and monitor performance metrics. Paired with CRM and EHR integrations, business development teams can better manage referral relationships to advance their organizations with certainty by improving their sales and marketing strategy. For more information on Trella Health and its post-acute, HME, and Infusion growth solutions, visit or follow Trella on Facebook, Twitter, and LinkedIn. Media Contact: Chandani Patel, press@ View original content to download multimedia: SOURCE Trella Health Sign in to access your portfolio
Scoop
27-06-2025
- Science
- Scoop
Farmers Must Be Told The Truth About GE Ryegrass Performance
AgResearch has issued the findings of the first animal feeding study results of genetically engineered High Metabolisable Energy (HME) ryegrass that contains two foreign genes, sesame and rice, show that GE ryegrass is not a viable technical fix. The GE rye grass for this study has not has Environmental Protection Authority approval.[1] The AgResearch $25 million GE rye grass trials conducted from 2017-2022, found that the field trials results did not meet the expected performance end points. The GE rye grass died back when under competition and if the temperature went over 26C, overall, there was a yield penalty. The planned feeding trials to be conducted in 2020 had to be postponed as the GE grass did not generate enough fodder to feed any animals. [2] Information, received under the OIA, from the Environmental Protection Agency (EPA) said they had not approved the grass trial and AgResearch reported that the GE rye grass for the lamb study, GE rye grass for the lamb study, was grown in separate pots in controlled laboratory conditions in the Palmerston North glass house and turned into non-viable dry matter (hay silage) taking 18 months to collect enough to carry out the experiment. [3] [4] The 24 lambs were divided into two groups 12 fed GE rye grass and 12 as controls. They were fed for 11days in special pens to record their emissions. Compared to the controls the methane levels were 7% for the GE rye grass vs 4.4% for the controls.[2] 'How often do farmers feed their lambs dried unviable 18 month hay grown in laboratory glasshouse conditions, never," said Claire Bleakley, president of GE Free NZ. This does not match the successful proven alternatives available today and farmers are being sold a GE failure. Linseed oil added to supplementary feeds have a higher methane reduction rate Multi-species forage is also delivering greater reduction (13%) in emissions than GE trials and research has shown the New Zealand based company growing red seaweed for supplements can reduce methane emissions by 90%. [5] [6] [7] The Gene Technology Bill will allow exempted, unregulated, unmonitored GE trials and release into the environment and the food chain with no safety, accountability or regulatory oversight. The drafting of the Bill did not even consider the poor results and failures of the New Zealand field trials. 'This unapproved study is a waste of money and a misleading farmer promotion for a failed GE experiment,' said Bleakley 'GE rye grass cross contamination will affect performance of the pure non-GE grass seed, once released it cannot be recalled". References: [2] Ministry of Business, Innovation and Employment, [3] [4] [5] [6]
Yahoo
11-06-2025
- Business
- Yahoo
Version 3.0 AI Automation Platform Launches at VGM's Heartland Conference
Darby 3.0 automates patient intake workflows from fax to EMR, helping HME providers scale without expanding teams WATERLOO, Iowa, June 11, 2025 /PRNewswire/ -- Darby, a leading provider of AI-powered automation for the home medical equipment (HME) industry, today announced the launch of Version 3.0 of its flagship platform at the 2025 Heartland Conference hosted by VGM. The enhanced suite delivers advanced AI capabilities designed to streamline patient intake operations. Version 3.0 represents a significant leap forward in Darby's mission to transform how home medical equipment companies manage their operations, from initial patient intake through payer qualification and compliance reporting. The new release employs artificial intelligence and machine learning technologies to automate complex workflows that have traditionally required extensive manual processing. "Version 3.0 delivers a complete transformation of the HME intake workflow," said Robin Y. Smith, CEO of Darby. "With fully automated fax processing, improved AI accuracy for payer qualification, and headless EMR uploads for qualified orders, we've eliminated many manual touchpoints in these workflows from referral to patient setup." Key capabilities in Version 3.0 include: Fully Automated Fax Intake Process: The platform automatically processes incoming faxes without manual intervention, sorting and labeling patient orders by product type Improved Payer Qualification Processing: Enhanced AI reviews qualification criteria against specific payer rulesets, including Medicare and commercial insurance guidelines, with superior accuracy Headless EMR Upload for Qualified Orders: Fully automatic and native integrations to EMR and Fax systems enable upload of qualified orders directly to EMR systems without requiring staff intervention Enhanced AI Accuracy: Improved machine learning algorithms deliver more precise document processing and qualification determination The Heartland Conference brings together hundreds of HME professionals, manufacturers, and partners to explore industry innovations. Darby's participation at the conference reinforces the company's commitment to supporting the VGM community and advancing the broader HME ecosystem. About Darby Darby specializes in AI and automation solutions designed specifically for the home medical equipment industry. Darby's software is SOC 2 Type II certified and HIPAA compliant. Backed by leading healthcare technology investors including Underscore VC, Flare Capital Partners and January Ventures, Darby serves HME customers nationwide and is committed to helping providers modernize their operations and scale efficiently. View original content: SOURCE Darby Inc Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
11-06-2025
- Business
- Yahoo
Version 3.0 AI Automation Platform Launches at VGM's Heartland Conference
Darby 3.0 automates patient intake workflows from fax to EMR, helping HME providers scale without expanding teams WATERLOO, Iowa, June 11, 2025 /PRNewswire/ -- Darby, a leading provider of AI-powered automation for the home medical equipment (HME) industry, today announced the launch of Version 3.0 of its flagship platform at the 2025 Heartland Conference hosted by VGM. The enhanced suite delivers advanced AI capabilities designed to streamline patient intake operations. Version 3.0 represents a significant leap forward in Darby's mission to transform how home medical equipment companies manage their operations, from initial patient intake through payer qualification and compliance reporting. The new release employs artificial intelligence and machine learning technologies to automate complex workflows that have traditionally required extensive manual processing. "Version 3.0 delivers a complete transformation of the HME intake workflow," said Robin Y. Smith, CEO of Darby. "With fully automated fax processing, improved AI accuracy for payer qualification, and headless EMR uploads for qualified orders, we've eliminated many manual touchpoints in these workflows from referral to patient setup." Key capabilities in Version 3.0 include: Fully Automated Fax Intake Process: The platform automatically processes incoming faxes without manual intervention, sorting and labeling patient orders by product type Improved Payer Qualification Processing: Enhanced AI reviews qualification criteria against specific payer rulesets, including Medicare and commercial insurance guidelines, with superior accuracy Headless EMR Upload for Qualified Orders: Fully automatic and native integrations to EMR and Fax systems enable upload of qualified orders directly to EMR systems without requiring staff intervention Enhanced AI Accuracy: Improved machine learning algorithms deliver more precise document processing and qualification determination The Heartland Conference brings together hundreds of HME professionals, manufacturers, and partners to explore industry innovations. Darby's participation at the conference reinforces the company's commitment to supporting the VGM community and advancing the broader HME ecosystem. About Darby Darby specializes in AI and automation solutions designed specifically for the home medical equipment industry. Darby's software is SOC 2 Type II certified and HIPAA compliant. Backed by leading healthcare technology investors including Underscore VC, Flare Capital Partners and January Ventures, Darby serves HME customers nationwide and is committed to helping providers modernize their operations and scale efficiently. View original content: SOURCE Darby Inc Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
